Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for...

32
10/2/2018 1 National Center for Emerging and Zoonotic Infectious Diseases Tom Chiller MD MPHTM Chief, Mycotic Diseases Branch Updates: Candida Epidemiology and Candida auris My usual Disclosure!

Transcript of Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for...

Page 1: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

1

National Center for Emerging and Zoonotic Infectious Diseases

Tom Chiller MD MPHTM

Chief, Mycotic Diseases Branch

Updates: Candida Epidemiology and Candida auris

My usual Disclosure!

Page 2: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

2

Candidemia surveillance

Page 3: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

3

Candidemia incidence by year and EIP site, 2009–2017

0.0

5.0

10.0

15.0

20.0

25.0

30.0

2009 2010 2011 2012 2013 2014 2015 2016 2017

Inci

den

ce p

er 1

00

.00

0 p

erso

ns

Year

CA CO GA MD MN NM NY OR TN

OR

Overall incidence: ~7/100,000

NM: 5.3

OR: 4.9CA: 4.8MN: 4.7

CO: 4.3

TN

MD

GA

Fluconazole Resistance (all species) by EIP Surveillance Site 2008-2017 (n=~8000 isolates)

1.8%

9.5%

5.7%

4.7%

2.3%

14.3%

4.1%

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

14.0%

16.0%

2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

% R

esi

stan

t

Year

CA

CO

GA

MD

MN

NM

NY

OR

TN

OR,CA: 0.0 %

On average, ~7% of all isolates collected through EIP are resistant to fluconazole (intrinsic or acquired resistance)

Page 4: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

4

Echinocandin Resistance (all species) by EIP Surveillance Site2008-2017 (n=~ 8000 isolates)

1.8%1.7%1.4%

1.9%

-1.0%

1.0%

3.0%

5.0%

7.0%

9.0%

11.0%

13.0%

15.0%

2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

% R

esi

stan

t

Year

CA

CO

GA

MD

MN

NM

NY

OR

TN

CA, NM, NY, OR, TN: 0.0%

On average ~ 1.5% of all isolates are resistant to echinocandins

Echinocandin-resistant C. glabrata by Surveillance Site

2008-2017 (n=2230 isolates)

5.9%6.3%

3.6%

6.5%

-1.0%

1.0%

3.0%

5.0%

7.0%

9.0%

11.0%

13.0%

15.0%

2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

% R

esi

stan

t

Year

CA

CO

GA

MD

MN

NM

NY

OR

TNCA, NM, NY, OR, TN: 0.0%

On average ~ 4% of C. glabrata isolates are resistant to echinocandins

Page 5: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

5

Resistance – US surveillance

• C. albicans still causes the highest percentages of Candida infections• Fluconazole resistance for C. albicans is <1%

• Overall fluconazole resistance is ~7%• Majority of this is C. glabrata and C. krusei

• Echinocandin resistance for C. albicans, C. tropicalis, C. parapsilosis, and C. krusei has remained <1%

C. glabrata MDR in the US

• 1.1% of all C. glabrata isolates were resistant to both fluconazole and echinocandins

• 28% of all echinocandin resistant C. glabrata are fluconazole resistant

• 11% of all fluconazole resistant C. glabrata are echinocandinresistant

Page 6: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

6

Candidemia burden estimate in 2017

Projected incidence rates of candidemia, by census division(per 100,000 population)

Based on projection from 1200 cases collected through EIP surveillance in 2017: 23,000 cases of candidemia occur each year in the United States3,000 deaths (all cause mortality within 1 week of candidemia)

Tsay et al, ID Week 2018

Proportion of IDU-associated candidemia cases by site, 2017

4.8%

7.8%

3.9%

16.7%

1.4%

29.4%

8.6%

25.8%

16.3%

0%

5%

10%

15%

20%

25%

30%

CA CO GA MD MN NM NY OR TN

Pro

po

rtio

n o

f C

ase

s w

ho

Inje

ct D

rugs

(%

)

Site

Zhang et al, ID Week 2018

OVERALL: 10.2%

Page 7: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

7

0%

5%

10%

15%

20%

25%

30%

2014 2015 2016 2017

Pro

po

rtio

n o

f ca

ses

wh

o in

ject

dru

gs (

%)

Year

MD

GA

OR

Tripling of proportion of cases

Trends in Proportion of IDU by year and site, 2014-2017 at select site with previous years of data

TN

Candidemia incidence by year and EIP site, 2009–2017

0.0

5.0

10.0

15.0

20.0

25.0

30.0

2009 2010 2011 2012 2013 2014 2015 2016 2017

Inci

den

ce p

er 1

00.0

00 p

erso

ns

Year

CA CO GA MD MN NM NY OR TN

OR

NM: 5.3

OR: 4.9CA: 4.8

MN: 4.7

CO: 4.3

Note increases in incidence of candidemia in TN likely due to increases in IDU

TN

MD

GA

Page 8: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

8

Summary

▪ One in 10 candidemia cases are associated with IDU in 2017

▪ Increase since 2014, most notably in TN and MD

▪ Significant differences between IDU-associated candidemia cases and non-IDU cases

– Median age: 35 vs. 62 years

– Hepatitis C: 55% vs. 6%

– TPN: 5% vs. 27%

– In-hospital mortality: 9% v. 27%

▪ CDC is investigating IDU-associated candidemia in more detail

Antimicrobial Resistance LabortoryNetwork (ARLN)

Page 9: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

9

ARLN Labs – Candida part of CORE pathogens tested

Objectives of the Candida ARLN program

▪ Set up regional lab network for susceptibility testing

▪ Track antifungal resistance among Candida/yeast species

▪ Identify emerging resistant species like Candida auris

Page 10: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

10

468 isolates tested in 2017

257

137

57

17

0

50

100

150

200

250

300

Northeast Central Southeast West

Page 11: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

11

Species identified – Top 10

169

106

3425

16 13 13 11 7 6

0

20

40

60

80

100

120

140

160

180

Resistance: C. glabrata (n=97)

▪ 2 isolates azole and echinocandin resistant

15.5% 3.1%Azoles Echinocandins

1.1%

Micafungin

Page 12: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

12

169 isolates confirmed as C. auris

153

115

109

101

0

20

40

60

80

100

120

140

160

180

Northeast Central Southeast

▪ 36% of all isolates

▪ 95% of all isolates identified as C. auris by the submitter

▪ 120 unique patients

Number of isolates Number of patients

C. auris update

Page 13: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

13

Candida?

A paradigm shift for Candida infectionsA Yeast that acts like a Bacteria!

▪ Resistance is the norm

▪ Thrives and persists on skin

▪ Contaminates patient rooms

▪ SPREADS IN HEALTHCARE SETTINGS

Page 14: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

14

C. auris epidemiology

Countries with Candida auris through 2015

Page 15: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

15

Countries reporting Candida auris in 2018Some hospitals with 40% candidemia

0

5

10

15

20

25

30

35

40

Nu

mb

er o

f cl

inic

al c

ases

New York New Jersey Maryland Illinois California Massachusetts

C. auris clinical cases reported by state — United States, 2013–August 2018

Solid: Confirmed case Striped: Probable case

~425 clinical cases~1180 clinical + screening cases

Page 16: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

16

States from which C. auris cases have been reported

Epidemiologic Characteristics of U.S. Cases

▪ Median age: 70; ~30% 30-day mortality

▪ Multiple underlying conditions, indwelling devices• Tracheostomy, central line, gastrostomy tube

▪ Extensive healthcare exposure • Acute care hospitals, LTACHs, vSNFs

▪ Patient have multiple other MDROs• CP-CRE is the most common co-colonizer

Per

cen

t res

ista

nt

Initial culture site of C. auris

Antifungal resistance of C. auris

Page 17: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

17

Healthcare abroad is risk factor for C. auris

▪ US C. auris cases are a result of initial introductions from abroad followed by local transmission

Isolates from U.S cases cluster to all four C. auris clades

South Americanclade

African clade

South Asianclade

East Asianclade

>300 clinical cases

> 700 additional patients colonized

Chow et al, Lancet ID in press

Page 18: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

18

CT, CA, and OK travel-related cases – South Asian clade

India Connecticut (CT)

India California (CA)

Pakistan Oklahoma (OK)

Chow et al, Lancet ID in press

Global C. auris antifungal resistance

0 10 20 30 40 50 60 70 80

Fluconazole

Amphotericin B

Echinocandins

% ResistanceN=848

Page 19: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

19

Resistance is clone-specific

• Southeast Asia• Nearly universally FluR, 40% AmpBR

• South America• Colombian isolates 25% FluR + AmpBR

• Venezuelan isolate are universally FluR

• Overall 8% EchinoR but higher in Venezuela

• Africa• Variable resistance, mostly FluR, some AmpBR

• East Asia• Universally susceptible

0

20

40

60

80

100

120

140

1 2 4 8 16 32 64 128 256

# o

f is

ola

tes

MIC ug/mL

MIC ug/mL

Resistance in C. auris is acquired, not intrinsic

Page 20: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

20

MDR C. auris

0 10 20 30 40 50 60 70 80 90

Pan susceptible

1 or more class

2 or more classes

Pan resistant

% ResistanceN=848

C. auris nationally notifiable in 2019

Page 21: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

21

C. auris Colonization: A new area for mycologists

C. auris Colonization

▪ Patients remain persistently colonized

• NYS has followed a few hundred patients

• 60% 90-day mortality

• Some colonized for over a year

• Only ~16 have “cleared” colonization

▪ Colonization means patients are:

• At risk for developing invasive infection

• 30 cases of BSI in ~600 colonized patients who are being followed 2016-2018

• Source of transmission to others

Page 22: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

22

C. auris Colonization

▪ Most sensitive (>90%) and cost-effective swab: axilla and groin

• Nares, rectal, and oral swabs have also been positive, but not as consistently as axilla/groin swabs

Detection through colonization screening

▪ Axilla and groin swabbing

▪ Enrichment broth method

• High salt/temperature

• ~25% more sensitive than direct plating

• Must hold plates for 10 days

Page 23: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

23

Question about When/Who to screen ?

▪ Contact tracing around a newly identified case

▪ Point prevalence surveys in places with some documented transmission

▪ Admission screening (pilot in NYS)

▪ Screening of patients with history of healthcare abroad, especially with a bad MDRO like CP-CRE

▪ Screening of patients in high-acuity long-term care facilities, especially those with CP-CRE and other MDROs

Rapid diagnostics

Real-time PCR

Page 24: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

24

Decolonization/source control

▪ Chlorhexidine? Another agent

▪ Antifungals? –terbinafine?

▪ Remove pressure of antibiotics and antifungals?

▪ Candida vaccine?

In vitro data on chlorhexidine looks good

Schelenz, Federation of Infection Societies Poster, 2017

Page 25: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

25

But…

▪ In vivo studies on reduction in burden of colonization have not been done

▪ Facilities where C. auris outbreaks have occurred have not seen improvements in incidence of colonization even when using aggressive CHG bathing

Environmental disinfection

Page 26: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

26

C. auris contaminates the hospital environment

Able to survive and persist on surfaces for weeks

Other places where C. auris has been cultured from:

Temperature probe

Madder et al (U.K.), bioRxviv 2017)Armstrong et al, unpublished

Page 27: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

27

Environmental disinfection: Quats don’t work well

Cadnum et al. 2017

Recommended but challenging

Not recommended

Limited data

Environmental disinfection – Hydrogen Peroxide

▪ In vitro studies promising

▪ Need real world assessments

Schelenz, Federation of Infection Societies Poster, 2017

Page 28: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

28

Environmental disinfection—UV Light

▪ Needs long exposure time at high intensity

Cadnum et al 2017

Questions about environmental disinfection

▪ What products to use ?

▪ When to use?

• Just for case patient room?

• The whole floor where the patient is admitted there?

• Pre-emptively at all long term care facilities with ventilated patients in an endemic area?

Page 29: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

29

Challenges for C auris

▪ Screening/colonization testing is not widely available and culture testing takes 10 days to call negative

▪ Rapid diagnostics are being developed but are not yet widely available

▪ Need decolonization methods

▪ Environmental disinfection options are limited (effective and safe alternatives to bleach are needed)

Where is it coming from?

Page 30: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

30

We need to live in Balance with the environment

Page 31: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

31

0

500

1000

1500

2000

2500

3000

3500

4000

Esti

mat

ed U

.S. A

gric

ult

ura

l Tri

azo

le U

se (

Met

ric

Ton

s)

Year

High Estimate

Low Estimate

Source: USGS Pesticide Data Use Project

Increasing Triazole Use in Agriculture

US Data

Page 32: Updates: Candida Epidemiology and Candida auris...Candida infections • Fluconazole resistance for C. albicans is

10/2/2018

32

For more information, contact CDC1-800-CDC-INFO (232-4636)TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Contact us at: [email protected]